<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7118423/results/search/drug/results.xml">
  <result pre="serology but are now labelled by phylogenetic clustering [6]. Only" exact="alpha" post="and beta coronavirus are of interest for human and"/>
  <result pre="[50]. Recently, scientists screened out four small-molecule drugs (prulifloxacin, tegobuvir," exact="nelfinavir" post="and bictegravir) with strong binding affinity to the main"/>
  <result pre="of China, antiviral therapy can be tried with interferon, lopinavir/ritonavir," exact="chloroquine" post="phosphate and umifenovir. These and other potentially effective drugs"/>
  <result pre="been initiated in February 2020 (ClinicalTrials.gov ID NCT04252664 and NCT04257656)." exact="Ribavirin" post="is a broad-spectrum antiviral nucleoside analogue that has been"/>
  <result pre="[67]. It has been shown in in vitro experiments that" exact="ribavirin" post="inhibits the replication of MERS-CoV and HCoV-OC43, but the"/>
  <result pre="[68]. Simultaneous use of interferon can reduce the dose of" exact="ribavirin" post="[69]. In a primate model, clinical symptoms of MERS"/>
  <result pre="symptoms of MERS could be improved by the combination of" exact="ribavirin" post="and type I interferon [70]. However, side effects of"/>
  <result pre="syndrome [72,73]. Therefore, further studies are needed to determine whether" exact="ribavirin" post="can effectively treat novel coronavirus pneumonia (COVID-19), and ribavirin"/>
  <result pre="whether ribavirin can effectively treat novel coronavirus pneumonia (COVID-19), and" exact="ribavirin" post="and interferon are still in clinical trials (Chinese Clinical"/>
  <result pre="(HIV) [74]. Lopinavir inhibits cleavage of the gag-pol protein, whilst" exact="ritonavir" post="inhibits cleavage of the gag-pol protein precursor and lopinavir"/>
  <result pre="whilst ritonavir inhibits cleavage of the gag-pol protein precursor and" exact="lopinavir" post="metabolism to increase the concentration of lopinavir [75]. It"/>
  <result pre="protein precursor and lopinavir metabolism to increase the concentration of" exact="lopinavir" post="[75]. It has been shown that lopinavir/ritonavir could inhibit"/>
  <result pre="treat SARS or MERS patients and show synergistic effects [69,82]." exact="Chloroquine" post="also has a strong antiviral effect on SARS-CoV-infected cells."/>
  <result pre="with virus–receptor binding by ACE2 terminal glycosylation [83,84]. In vitro," exact="chloroquine" post="can enhance the effects of other antiviral drugs [38]."/>
  <result pre="the viral polymerase and the proofreading exoribonucleasemBio9201810.1128/mBio.00221-18pii: e00221-18 66WangM.CaoR.ZhangL.YangX.LiuJ.XuM.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="of interferon-α2b and ribavirinSci Rep32013168610.1038/srep0168623594967 70FalzaranoD.de WitE.RasmussenA.L.FeldmannF.OkumuraA.ScottD.P.Treatment with interferon-α2b and" exact="ribavirin" post="improves outcome in MERS-CoV-infected rhesus macaquesNat Med1920131313131710.1038/nm.336224013700 71ZumlaA.ChanJ.F.AzharE.I.HuiD.S.YuenK.Y.Coronaviruses—drug discovery"/>
 </snippets>
</snippetsTree>
